Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Expand Range of Essential Drugs, Limit Coverage of Off-Year Re-Pricing: FPMAJ Member Associations
September 26, 2022
- MHLW Panel OKs 65 More Health Damage Claims for COVID-19 Vaccines
September 26, 2022
- Enhertu, BMS’s Luspatercept Grab Orphan Designation
September 22, 2022
- Japan Healthcare Spending Logs 44.2 Trillion Yen in FY2021, Up 4.6% on Post-Pandemic Rebound
September 21, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
- 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
- MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
- MHLW Eyes Diet Submission of Bill to Amend Cannabis Control Act Next Year: Official
September 20, 2022
- Japan Detects 14 More Probable Cases of Pediatric Hepatitis
September 20, 2022
- Japan OKs Additional Indications for 12 Fertility Treatments
September 20, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- MHLW to Submit Bill for Integrating Drug Supply Info in Extraordinary Diet Session: Official
September 15, 2022
- MHLW to Simplify Optimal-Use Guidelines for Drugs after Reexamination Period
September 15, 2022
- Contraindication Lifted for Concurrent Use of Adempas and HIV Protease Inhibitors
September 14, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- MHLW Panel Recognizes 2 More Deaths Linked to COVID Jabs
September 13, 2022
- MHLW to Survey Impact of Price Surge, FX on Drugs with High Need for Stable Supply
September 13, 2022
- MHLW Panels’ Decision to Put a Hold on Shionogi’s COVID Pill Based on Regulatory Science: Official
September 12, 2022
- LDP Project Team Proposes Deeper Discussions on Structural Drug Pricing Issues
September 12, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…